2015-11-19

Camurus to be listed on Nasdaq Stockholm

Camurus announces initial public offering on Nasdaq Stockholm. The company plans a new shares issue to a value of SEK 500 million net - a market capitalization of appr. SEK 2 billion.

Camurus AB and Sandberg Development AB have, in order to promote Camurus’ continued growth and development, decided to broaden the shareholder base by a new share issue and minor sale of existing shares . The Board of Directors of Camurus has therefore applied for the Company’s shares to be listed on Nasdaq Stockholm. Nasdaq Stockholm has approved the Company's application subject to customary conditions. Expected first day of trading is 3 December 2015. Today, November 19, 2015, the Company publishes its prospectus and announces the price range as well as other terms and conditions for the Offering.

For more information, please go to www.camurus.com

Latest news

2020-07-16

Camurus' Interim Report Second Quarter 2020

”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”

Read more

2020-06-24

Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

Read more

2020-06-23

Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

Read more

2020-05-07

Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

Read more

2020-04-08

Camurus Annual Report for 2019

Camurus Annual Report for 2019 is now available at the company´s website.

Read more